Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports

Executive Summary

The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.

You may also be interested in...



Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II

Roche's development plans for a follow-on Avastin product have been called into question after the company noted briefly in its third-quarter earnings update that the drug failed in a Phase II study in colorectal cancer patients.

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

AP000837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel